17.3%, Seattle, or 22.5%, Baltimore). The mortality declined since 1997 (from 22% to 9%; P 5.06, Seattle, and from 36% to 14%; P 5.04, Baltimore), with the introduction of defibrotide being the only relevant change in the management of patients. This occurred even though the severity of VOD was similar in both periods. Among those with MOF, only 2 of 8 (25%) receiving defibrotide died versus 14 of 18 (78%) receiving other treatments (P 5 .007). Myeloablative conditioning, previous liver disease, poor performance status, and alternative donors were the variables with higher impact on VOD development. In summary, although VOD remains a dreaded early complication of HSCT, technical and therapeutic progress in recent decades have notably reduced its incidence and improved the outcome.
INTRODUCTION
Hepatic sinusoidal obstruction syndrome, commonly know as veno-occlusive disease (VOD) of the liver, is an early complication of hematopoietic stem cell transplantation (HSCT). This syndrome is characterized by clinical features of rapid weight gain, ascites, painful hepatomegaly, and jaundice [1, 2] .
As with any syndrome, the diagnosis of VOD is based on clinical criteria and does not require histologic or hemodynamic confirmation. The diagnostic criteria described by the Seattle group [3] are the most widely used, even though those described by the Baltimore group [4] permit a more precise diagnosis. The clinical course of VOD is usually self-limiting, but severe cases result in a very high mortality rate [5] . There is no consensus on a suitable grading system for the severity of this syndrome. Usually, it is classified as mild, moderate, or severe retrospectively, based on its evolution [6] . Given the absence of predictable models applicable to all cases, most authors consider that the evolution to multiorgan failure (MOF) is the most reliable marker of severity and predictor of poor outcome [5] .
Several patient-and transplant-related risk factors have been associated with VOD, with the most important being the disease and the liver status, the type of HSCT, and the intensity of the cytoreductive therapy used in the conditioning regimen [1, 2, 4, 7, 8] . The incidence of VOD rarely exceeds 5% in patients receiving an autologous HSCT but can be observed in up to 60% of patients after allogeneic HSCT (allo-HSCT). A prospective study performed by the European Group for Blood and Marrow Transplantation (EBMT) showed that the presence of several risk factors have an additive effect on the incidence of VOD [8] . This fact and the use of different diagnostic criteria explain why the incidence of VOD ranges from 0% to 60% in the published series.
Recently, a well-conducted retrospective review of 135 studies performed between 1979 and 2007 showed that the mean incidence of VOD was 13.7% (17.3% and 9.6% using the Seattle and Baltimore criteria, respectively). This incidence was lower in the period 1979 to 1994 than between 1994 and 2007 (11.5% vs 14.6%; P \ .05). The mortality rate from severe VOD was 84.3%, mostly occurring in patients with MOF. The authors concluded that the incidence of VOD was lower than that observed in some early reports, and it did not decrease over the years despite the recent introduction of the reduced-intensity conditioning (RIC) to prepare patients undergoing allo-HSCT.
After considering these results, we decided to analyze our series of patients receiving allogeneic HSCT, as our feeling was that the incidence of VOD has been declining and its outcome improving over the years. Our institution has a large and prolonged experience in the diagnosis and management of this complication [7] [8] [9] [10] [11] [12] . For that reason, we were able to analyze a homogeneous and carefully evaluated series of 845 consecutive cases of allo-HSCT performed during the last 24 years.
PATIENTS AND METHODS
Between January 1985 and July 2008, 845 allo-HSCT procedures were performed on 763 patients in our unit. The main characteristics of the patients and the most relevant aspects of HSCT are shown in Table 1 . Briefly, their median age was 36 years and slightly more than one-half (58%) were men. Primary diseases were acute myelogenous or lymphoblastic leukemia (n 5 363), chronic myelogenous leukemia (CML) (n 5 238), myelodysplastic syndrome (MDS) (n 5 55), non-Hodgkin and Hodgkin's lymphomas (n 5 75), multiple myeloma (MM) (n 5 41), chronic lymphocytic leukemia (CLL) (n 5 33), and severe aplastic anemia (SAA) (n 5 31). Malignancies were in early (first complete remission [CR] or a chronic phase [CP]), intermediate ($2 CR or second CP or accelerated phase), or advanced phases in 46%, 17%, and 37% of cases, respectively. Performance status was good (Karnofsky score $90) in 71% of HSCT. Ten percent and 6% of the patients had a previous liver disease (viral infection or infiltrative) or increased levels of alanine transaminase at HSCT, respectively.
Conditioning was mainly based on cyclophosphamide (Cy) 120 mg/kg 1 total body irradiation (TBI)-from 10 Gy in a single dose to 13.5 Gy in 4 fractions-(69%), fludarabine 1 others (16%), or busulfan (Bu) 16 mg/kg 1 Cy 120 mg/kg (7%). In 18% of HSCT, we used an RIC. The stem cell source was bone marrow in 62% of cases, mobilized peripheral blood in 46%, and umbilical cord blood in 2%. Cyclosporine and short methotrexate (54%), prednisone (32%), or mycophenolate (12%) where mainly used for graftversus-host disease (GVHD) prophylaxis. Ex vivo T cell depletion was performed in 19% of transplantations using different methods, and 6% received antithymocyte globulin (ATG). Alternative donors were used in 197 cases (23%), and 123 patients had received a previous autologous (n 5 61) or allo-HSCT (n 5 62).
All patients were housed in HEPA/LAF rooms during the neutropenic phase and received the following prophylaxis: mesna (Cy-containing regimes), phenytoin (Bu-containing regimes), quinolones and acyclovir (during neutropenia), fluconazole (up to day 160 following HSCT), and cotrimoxazole or inhalated pentamidine. We do not use pharmacologic measures routinely for VOD prophylaxis, but, occasionally, some individually selected patients with several risk factors for this complication (usually second transplants performed early after the first HSCT with a previous liver disease) received low-molecular-weight heparin (LMWH) during conditioning and up to day 114. No patients received ursodeoxycholic acid.
Definition of VOD and Its Severity and Management
Diagnosis of VOD was established using both Seattle and Baltimore clinical criteria [4, 6] whenever these clinical data could not be attributed to other causes such as sepsis, drug toxicity, or heart failure. Based on previous observations by our group [12] , we did not limit this diagnosis to the classical 21 days after HSCT, and all suspicious cases appearing in the first 60 days were evaluated. The severity of VOD was classified retrospectively using a modified Seattle definition. When all the signs and symptoms of VOD disappeared without treatment or only with fluid and sodium restriction and diuretics, VOD was considered ''mild.'' Patients requiring other therapeutic interventions were classified as having ''moderate'' VOD. Those cases not resolved by day 1100, those who died before this date with an active VOD, or in whom death was directly attributable to VOD were considered to have ''severe'' VOD. Additionally, the presence of MOF (renal, respiratory, or central nervous system dysfunction clearly related with VOD) was enough to consider the episode as a ''severe'' episode.
After our initial studies [9, 10] , in which patients were evaluated prospectively by means of a transjugular approach, we only used this technique to confirm the origin of the liver disturbance before adopting any therapeutic measures that could be hazardous to the patient. As VOD is a syndrome, in any case we used the result of hemodynamic study to establish or modify this diagnostic.
Patients with VOD were treated with sodium and fluid restriction, diuretics, and if progressing, dopamine, sodium heparin, LMWH, or recombinant tissue plasminogen activator depending on the severity. Since 2000, patients with a VOD that fulfilled the Baltimore criteria received defibrotide (DF) (provided by Gentium S.p.A., Como, Italy) for compassionate purposes at a dose of 10 mg/kg every 6 hours intravenously for a minimum of 14 days. 
Statistical Analyses
The incidence of VOD after transplantation was calculated using cumulative incidence (CumI) curves in a competing risks setting, with death being treated as a competing event to VOD. In the population of patients having experienced VOD, the incidence of death from VOD was also estimated by cumulative incidence curves from the date of diagnosis of VOD; the competing event was death up to day 1100 from another cause. Univariate analyses were performed using Gray's test. Multiple comparisons on cumulative incidence of VOD in different subgroups of patients were taken into account using the Bonferroni correction with P\.016. Statistical analyses will be performed with TIBCO Spotfire S1Ò 8.1 (TIBCO Software Inc. Palo Alto, CA) for Windows software package.
Risk factors for VOD included in the uni-and multrivariate analysis were age, sex, underlying disease, status of the disease at HSCT (early, intermediate, advanced), Karnofsky status at HSCT ($90 vs \90), previous liver disease, increased transaminase levels at HSCT, year of HSCT, transplantation number (first vs subsequent), conditioning intensity (myeloablative conditioning [MAC] vs RIC), conditioning agents (Bucontaining vs others; TBI $10 cGy vs non-TBI; fludarabine vs others), GVHD prophylaxis (methotrexate vs mycophenolate vs others), ex vivo T cell depletion, source of stem cells (bone marrow [BM], peripheral blood, cord blood), type of donor (HLA identical sibling, other family members, unrelated), VOD prophylaxis, and use of ATG. To compare dichotomous variables, the Fisher (2-tailed) and chi-square tests were used for univariate analysis. Logistic regression was performed and included all variables that were significant in univariate (p\0.05), and a backward stepwise selection (Wald) was used to identify the final model. Results were expressed as odds ratios (OR) and 95% confidence intervals (CI). These analyses were performed using SPSS Statistics version 17.0.0 (SPSS, Inc, Chicago, IL), and grouped numerical data were expressed as mean 6 standard deviation where appropriate.
RESULTS
One hundred seventeen and 73 patients developed a VOD following the Seattle and the Baltimore diagnostic criteria. This represents a CumI of 13.8% 6 1% and 8.8% 6 1%, respectively. Their main clinical characteristics are shown in Table 2 . Only 1 patient developed VOD after the classical day 121 (day 144). Forty-four patients only fulfilled the Seattle diagnostic criteria; none of them developed MOF or had a severe VOD. Weight gain and jaundice were the most usual clinical manifestations (almost 100% of patients); 26 developed MOF (renal failure in 16, pulmonary in 20, and neurologic in 5).
When comparing the CumI of VOD using Baltimore criteria in the 3 main groups of HSCT cases (Table 3 )-(1) MAC before 1997 (n 5 385); (2) MAC since 1997 (n 5 310); and (3) RIC since 1997 (n 5 142)-we observed that in the whole series the CumI of VOD was higher in the period 1985 to 1996 than in 1997 to 2008 (11.5% 6 2% vs 6.5% 6 1%; P 5 .01). This difference was mainly because of the increasing numbers of RIC-HSCT cases in the second period with a CumI of VOD of 2.1% 6 1.2% (vs 8.4% 6 1.6% in MAC since 1997; P 5 .011). Similar results were obtained when we performed the same analysis in patients receiving an HSCT from HLA-identical siblings. However, when we analyzed patients receiving an HSCT from alternative donors, we additionally observed a clear reduction on the incidence of VOD when comparing those receiving a MAC-HSCT before or since 1997 (32.7% 6 7% vs 10.5% 6 3%; P 5 .002). In this subgroup of patients, the incidence of VOD among those receiving an RIC-HSCT was similar to that observed among those receiving a MAC-HSCT (7.6% 6 4% vs 10.5% 6 3%; not significant, ns). All patients had hydro-saline restriction. Before 2000, patients with a severe VOD were treated as follows: dopamine perfusion (11 cases); hemodialysis (2 cases); transjugular intrahepatic portosystemic shunt (3 cases); heparin (3 cases); or recombinant tissue plasminogen activator (2 cases). Since 2000, 19 patients with a VOD fulfilling the Baltimore criteria were treated with DF.
Because it was included in our early studies or because of doubts regarding the differential diagnosis, a hemodynamic study of the liver was performed in 49 patients (42%). The hepatic venous gradient pressure (HVGP) was $10 mmHg in 11 patients (22%) (17 6 7 mmHg). Of them, 5 died because of VOD and 3 died before day 1100 because of interstitial pneumonia 6 GVHD. None of the 38 patients with an HVGP lower than 10 mmHg (5 6 2 mmHg) died as a consequence of VOD, but 12 died early after HSCT because of interstitial pneumonia (n 5 7), GVHD (n 5 2), infection (n 5 2), or graft failure (n 5 1).
In 79 (Seattle) or 38 (Baltimore) cases, VOD had a mild or intermediate severity and resolved by day 1100. Of these, 23 died early after HSCT (before day 1100) because of intercurrent complications (mainly interstitial pneumonitis and infections) ( Table 2) . Thirty-eight (Seattle) or 35 (Baltimore) patients had severe VOD (26 with MOF). In 20 of these patients, the death was clearly attributable to VOD. This represents a CumI of death from VOD of 17% 6 3% or 27% 6 5% using Seattle or Baltimore criteria, respectively. Only 8 (Seattle) or 7 (Baltimore) resolved their VOD and survived .100 days. The remaining cases died because of intercurrent causes with or without an active VOD ( Univariate analysis including all relevant variables showed that those factors with an adverse impact on the incidence of VOD were as follows ( Table 4 ): HSCT performed before 1997 (P 5 .014); a diagnosis of CML (P 5 .053); MAC (P 5 .001); alternative donors (P 5 .001); use of BM (P 5 .025); T cell-repleted graft (P 5 .017); abnormal liver and/ or transaminase levels before HSCT (P 5 .001 and P 5 .004, respectively); and a Karnofsky index \90 (P 5 .02). In the multivariate analysis, only CML (OR 5 1.96; 95% CI 5 1.1-3.6), MAC (OR 5 7.99; 95% CI 5 2.3-28), alternative donors (OR 5 3; 95% CI 5 1.7-5.4), previous liver disease (OR 5 3.4; 95% CI 5 1.7-6.6), and poor performance status (OR 5 3.2; 95% CI 5 1.8-5.7) retained statistical significance.
DISCUSSION
To our knowledge, this is the largest series from a single center focused on the analysis of this early complication of HSCT. The most relevant aspect of our cohort was its homogeneity. All HSCT procedures were made following very similar guidelines for transplantation, and the diagnoses and management of VOD were done by a group of physicians and nurses focused on the study of this complication since 1985. The main conclusions of our analysis can by summarized in 4 points.
1. The incidence of VOD: As observed in the EBMT prospective study [8] and in the recent analysis of all published reports including more than 50 patients [5] , the mean incidence of VOD seemed to be lower than published in early reports (around 9% using the Baltimore criteria and 14% with the Seattle criteria). However, our results do not confirm the increase in the incidence of VOD in the recent years observed by Coppell et al. [5] (11% vs 15%; P \.05 when comparing HSCT performed before or after 1994). In our series, analyzing the cumulative incidence to evaluate competitive events, when comparing 2 identical periods of 12 years, we observed a lower CumI since 1997 (11.5% vs 6.5% using Baltimore criteria) attributable in part to RIC-HSCT (incidence of 2.1%), but also to a clear reduction in the CumI of VOD among MAC-HSCT procedures using alternative donors (32.7% vs 10.5%) in this second period.
Probably the improvement of supportive measures, the increasing use of peripheral blood stem cells, the selection of donors based on high-resolution typing for HLA-A, B, C, DRB1, and DQB1 loci, and the introduction of i.v. busulfan have contributed to this improvement. Interestingly, when RIC was applied to patients receiving HSCT from alternative donors, the CumI of VOD was similar to that observed with MAC (10.5% vs 7.6%). This observation suggests that the effect of allo-reactivity on hepatic sinusoids observed in clinical [6] and experimental approaches [13, 14] acts against the beneficial effect of using less toxic conditioning.
2. Transjugular studies: For the daily management of these patients, the only usefulness of these studies was to know in advance the severity of the VOD.
As in most patients with HVGP $10 mmHg, the death was direct or indirectly related to VOD. However, being a potentially harmful procedure, it should only be performed in centers with experience and in selected cases where it is deemed essential to obtain a correct differential diagnosis. 3. Risk factors for VOD: Univariate analysis confirmed the most relevant previously described risk factors for this complication as being the patient's status, conditioning intensity, previous liver disease, use of peripheral blood stem cells, T cell depletion of the graft, and type of donor [1] . We do not have clear explanation for the slightly higher incidence of VOD observed in patients with CML, but this probably results from a combination of factors, because 10 of 28 received oral Bu before HSCT, 19 of 28 had a unrelated donor HSCT, 15 of 25 a very intensive conditioning, and all of them had an active disease at HSCT. In multivariate analysis, a diagnosis of CML, use of MAC, alternative donors, previous liver disease, and a poor patient status maintained statistical significance, with MAC being the most predictive variable (OR 5 7.99). A low incidence of VOD among RIC recipients has been observed in most reports of this new type of HSCT, and this fact was confirmed in a large series of 237 cases using RIC-HSCT, most of them using Bu therapy [15] . The incidence observed among RIC recipients in our series was even lower, probably as a consequence of the low incidence of RIC using Bu (26 of 142). Of note was the fact that all RIC patients with VOD in our series had several risk factors for this complication (previous autologous SCT, poor performance status, and previous liver disease). 4. VOD evolution: Fortunately, up to 90% of patients with nonsevere VOD improved after several days with only supportive measures, or more recently with DF administration. This is especially true for patients with only 2 clinical criteria of VOD following the Seattle criteria, as all showed a rapid improvement. This observation confirms that the application of therapeutic measures, other than water and sodium restriction, should only be considered in patients fulfilling the Baltimore criteria. Undoubtedly, the progression to MOF is the best marker of the severity of the disease. Because the Seattle classification of severity is retrospective, it has little relevance for the clinical management of patients. For that reason, the evolution to MOF (or a high HVGP if available) must be considered as the best indicator of severity and predictor of poor outcome. In our series, we have observed a clear lower probability of dying from VOD since 1997 (14% vs 36% before), and the only relevant change in the patients management was the introduction of DF. When comparing mortality rate by VOD before and after introducing this drug, the results were significantly different, even though the severity of the treated cases was similar.
In addition, only 2 of 8 (25%) patients with MOF receiving DF died of VOD, versus 14 of 18 (78%) who received other treatments (P 5 .007). This incidence was similar to that observed in others series of severe cases of VOD not receiving DF [5] . These data, together with recent observations showing that DF when used prophylactically reduces not only the incidence of VOD but also the incidence of GVHD [16] , that it has a potent antithrombotic effect in human microvascular endothelial cells models [17] , and that it produces few and acceptable secondary effects [18] , indicate that this agent probably could be of great interest in high-risk patients receiving MAC-HSCT from unrelated donors.
In summary, our study shows that, although VOD remains a dreaded early complication of HSCT, technical progress in recent decades has notably reduced its incidence and improved the outcome for patients. RIC has played a major role in this, but the improvement of results among recipients receiving an unrelated HSCT has also contributed. Interestingly, the beneficial effect of RIC seems to disappear in an unrelated transplant setting. The use of DF, as well as progress in patient management, has probably contributed to the clear reduction of the morbidity and mortality associated with VOD, but this can only be confirmed by prospective randomized studies.
